TY - JOUR
T1 - Safety and immunogenicity of an anti-zika virus DNA vaccine
AU - Tebas, Pablo
AU - Roberts, Christine C.
AU - Muthumani, Kar
AU - Reuschel, Emma L.
AU - Kudchodkar, Sagar B.
AU - Zaidi, Faraz I.
AU - White, Scott
AU - Khan, Amir S.
AU - Racine, Trina
AU - Choi, Hyeree
AU - Boyer, Jean
AU - Park, Young K.
AU - Trottier, Sylvie
AU - Remigio, Celine
AU - Krieger, Diane
AU - Spruill, Susan E.
AU - Bagarazzi, Mark
AU - Kobinger, Gary P.
AU - Weiner, David B.
AU - Maslow, Joel N.
N1 - Funding Information:
Supported by GeneOne Life Science and in part by a grant (AI069534) to the Clinical Trials Unit at the University of Pennsylvania from the National Institutes of Health. Inovio Pharmaceuticals (codeveloper of the vaccine) provided electroporation devices and supplies. Dr. Weiner is supported in part by a grant (R01-AI092843) from the Intramural Research Program of the National Institute of Allergy and Infectious Diseases and through the W.W. Smith Chair in Cancer Research.
Publisher Copyright:
Copyright © 2017 Massachusetts Medical Society.
PY - 2021/9/16
Y1 - 2021/9/16
N2 - Background: Although Zika virus (ZIKV) infection is typically self-limiting, other associated complications such as congenital birth defects and the Guillain-Barre syndrome are well described. There are no approved vaccines against ZIKV infection. Methods: In this phase 1, open-label clinical trial, we evaluated the safety and immunogenicity of a synthetic, consensus DNA vaccine (GLS-5700) encoding the ZIKV premembrane and envelope proteins in two groups of 20 participants each. The participants received either 1 mg or 2 mg of vaccine intradermally, with each injection followed by electroporation (the use of a pulsed electric field to introduce the DNA sequence into cells) at baseline, 4 weeks, and 12 weeks. Results: The median age of the participants was 38 years, and 60% were women; 78% were White and 22% Black; in addition, 30% were Hispanic. At the interim analysis at 14 weeks (i.e., after the third dose of vaccine), no serious adverse events were reported. Local reactions at the vaccination site (e.g., injection-site pain, redness, swelling, and itching) occurred in approximately 50% of the participants. After the third dose of vaccine, binding antibodies (as measured on enzyme-linked immunosorbent assay) were detected in all the participants, with geometric mean titers of 1642 and 2871 in recipients of 1 mg and 2 mg of vaccine, respectively. Neutralizing antibodies developed in 62% of the samples on Vero-cell assay. On neuronalcell assay, there was 90% inhibition of ZIKV infection in 70% of the serum samples and 50% inhibition in 95% of the samples. The intraperitoneal injection of postvaccination serum protected 103 of 112 IFNAR knockout mice (bred with deletion of genes encoding interferon-α and interferon-β receptors) (92%) that were challenged with a lethal dose of ZIKV-PR209 strain; none of the mice receiving baseline serum survived the challenge. Survival was independent of the neutralization titer. Conclusions: In this phase 1, open-label clinical trial, a DNA vaccine elicited anti-ZIKV immune responses. Further studies are needed to better evaluate the safety and efficacy of the vaccine.
AB - Background: Although Zika virus (ZIKV) infection is typically self-limiting, other associated complications such as congenital birth defects and the Guillain-Barre syndrome are well described. There are no approved vaccines against ZIKV infection. Methods: In this phase 1, open-label clinical trial, we evaluated the safety and immunogenicity of a synthetic, consensus DNA vaccine (GLS-5700) encoding the ZIKV premembrane and envelope proteins in two groups of 20 participants each. The participants received either 1 mg or 2 mg of vaccine intradermally, with each injection followed by electroporation (the use of a pulsed electric field to introduce the DNA sequence into cells) at baseline, 4 weeks, and 12 weeks. Results: The median age of the participants was 38 years, and 60% were women; 78% were White and 22% Black; in addition, 30% were Hispanic. At the interim analysis at 14 weeks (i.e., after the third dose of vaccine), no serious adverse events were reported. Local reactions at the vaccination site (e.g., injection-site pain, redness, swelling, and itching) occurred in approximately 50% of the participants. After the third dose of vaccine, binding antibodies (as measured on enzyme-linked immunosorbent assay) were detected in all the participants, with geometric mean titers of 1642 and 2871 in recipients of 1 mg and 2 mg of vaccine, respectively. Neutralizing antibodies developed in 62% of the samples on Vero-cell assay. On neuronalcell assay, there was 90% inhibition of ZIKV infection in 70% of the serum samples and 50% inhibition in 95% of the samples. The intraperitoneal injection of postvaccination serum protected 103 of 112 IFNAR knockout mice (bred with deletion of genes encoding interferon-α and interferon-β receptors) (92%) that were challenged with a lethal dose of ZIKV-PR209 strain; none of the mice receiving baseline serum survived the challenge. Survival was independent of the neutralization titer. Conclusions: In this phase 1, open-label clinical trial, a DNA vaccine elicited anti-ZIKV immune responses. Further studies are needed to better evaluate the safety and efficacy of the vaccine.
UR - http://www.scopus.com/inward/record.url?scp=85115301430&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115301430&partnerID=8YFLogxK
U2 - 10.1056/NEJMoa1708120
DO - 10.1056/NEJMoa1708120
M3 - Article
C2 - 28976850
AN - SCOPUS:85115301430
SN - 0028-4793
VL - 385
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 12
M1 - e35
ER -